515 related articles for article (PubMed ID: 12010861)
21. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
22. Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons.
Fanjul AN; Bouterfa H; Dawson M; Pfahl M
Cancer Res; 1996 Apr; 56(7):1571-7. PubMed ID: 8603404
[TBL] [Abstract][Full Text] [Related]
23. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.
Klopper JP; Berenz A; Hays WR; Sharma V; Pugazhenthi U; Janssen J; Singh M; Bissonnette RP; Haugen BR
Clin Cancer Res; 2008 Jan; 14(2):589-96. PubMed ID: 18223235
[TBL] [Abstract][Full Text] [Related]
24. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Fu J; Ding Y; Huang D; Li H; Chen X
Cancer Lett; 2007 Apr; 248(1):153-63. PubMed ID: 17027148
[TBL] [Abstract][Full Text] [Related]
25. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.
Darro F; Cahen P; Vianna A; Decaestecker C; Nogaret JM; Leblond B; Chaboteaux C; Ramos C; Pétein M; Budel V; Schoofs A; Pourrias B; Kiss R
Breast Cancer Res Treat; 1998 Sep; 51(1):39-55. PubMed ID: 9877028
[TBL] [Abstract][Full Text] [Related]
26. Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids.
Toma S; Isnardi L; Riccardi L; Bollag W
Anticancer Res; 1998; 18(2A):935-42. PubMed ID: 9615744
[TBL] [Abstract][Full Text] [Related]
27. Pattern of retinoid-induced teratogenic effects: possible relationship with relative selectivity for nuclear retinoid receptors RAR alpha, RAR beta, and RAR gamma.
Elmazar MM; Reichert U; Shroot B; Nau H
Teratology; 1996 Mar; 53(3):158-67. PubMed ID: 8761883
[TBL] [Abstract][Full Text] [Related]
28. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions.
Mehta RG; Williamson E; Patel MK; Koeffler HP
J Natl Cancer Inst; 2000 Mar; 92(5):418-23. PubMed ID: 10699072
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
30. Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition.
Pignatello MA; Kauffman FC; Levin AA
Toxicol Appl Pharmacol; 1997 Feb; 142(2):319-27. PubMed ID: 9070355
[TBL] [Abstract][Full Text] [Related]
31. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Brown PH; Subbaramaiah K; Salmon AP; Baker R; Newman RA; Yang P; Zhou XK; Bissonnette RP; Dannenberg AJ; Howe LR
Cancer Prev Res (Phila); 2008 Aug; 1(3):208-14. PubMed ID: 19138958
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
Yen WC; Prudente RY; Lamph WW
Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
[TBL] [Abstract][Full Text] [Related]
33. Multiple factors contribute to the toxicity of the aromatic retinoid TTNPB (Ro 13-7410): interactions with the retinoic acid receptors.
Pignatello MA; Kauffman FC; Levin AA
Toxicol Appl Pharmacol; 1999 Sep; 159(2):109-16. PubMed ID: 10495774
[TBL] [Abstract][Full Text] [Related]
34. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
[TBL] [Abstract][Full Text] [Related]
35. Marked improvement induced in photoaged skin of hairless mouse by ER36009, a novel RARgamma-specific retinoid, but not by ER35794, an RXR-selective agonist.
Sakuta T; Kanayama T
Int J Dermatol; 2006 Nov; 45(11):1288-95. PubMed ID: 17076708
[TBL] [Abstract][Full Text] [Related]
36. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.
Cohen LA; Pittman B; Wang CX; Aliaga C; Yu L; Moyer JD
Cancer Res; 2001 Dec; 61(24):8683-8. PubMed ID: 11751385
[TBL] [Abstract][Full Text] [Related]
37. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.
Christov K; Grubbs CJ; Shilkaitis A; Juliana MM; Lubet RA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5488-96. PubMed ID: 17875779
[TBL] [Abstract][Full Text] [Related]
38. Retinoids suppress premalignant MCF10AT but not malignant MCF10CA1a breast epithelial cells in vivo. Role of retinoic acid receptor beta2 expression.
Peng X; Wood S; Bratescu L; Shilkaitis A; Christov K
Cancer Lett; 2005 May; 222(2):153-63. PubMed ID: 15863264
[TBL] [Abstract][Full Text] [Related]
39. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
40. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells.
Zou C; Liebert M; Zou C; Grossman HB; Lotan R
J Urol; 2001 Mar; 165(3):986-92. PubMed ID: 11176527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
